Kidswell Bio
4584.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2022-03 | 2021-03 | 2020-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥6.6bn | ¥5.1bn | — | ¥1.6bn | ¥997m | ¥1.1bn |
| Operating income | −¥139m | ¥28m | — | −¥919m | −¥970m | — |
| Ordinary income | −¥375m | ¥5m | — | −¥953m | −¥991m | −¥1.2bn |
| Net income (owners) | −¥414m | −¥21m | — | −¥535m | −¥1.0bn | −¥7.3bn |
| Total assets | ¥6.1bn | ¥7.0bn | — | ¥3.5bn | ¥3.9bn | ¥3.6bn |
| Net assets / equity | ¥1.7bn | ¥1.4bn | ¥831m | ¥1.7bn | ¥1.6bn | ¥1.5bn |
| Operating cash flow | −¥1.1bn | ¥937m | — | −¥1.2bn | −¥1.3bn | −¥1.3bn |
| EPS (basic) | ¥-8.48 | ¥-0.52 | — | ¥-17.35 | ¥-34.79 | ¥-264.65 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 66 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 27 figures · EDINET |
22 more reports are still being processed.